




The relative strengths and weaknesses of Kuvatris Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kuvatris Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 1.4% points. The greatest weakness of Kuvatris Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is 3.6%, being 241% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	2,204
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,096
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,197
Other Revenues	0
Property and Equipment	0
Research and Development	1,787
Selling, General and Administrative Expense	8,817

Output Variable	Value in 1000 USD
Assets	2,204
Liabilities	2,096
Expenses	10,604
Revenues	0
Stockholders Equity	109
Net Income	-14,802
Comprehensive Net Income	-14,802
BaseVar	9,551
ECR before LimitedLiability	-677%
Economic Capital Ratio	3.6%